Actinium Pharmaceuticals Inc (ATNM)

$1.27 +0.02 (1.60%)
Market Cap 39.00M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,000
Avg Vol 192,430
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 24%
Beta -0.25
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Xarevira
Xarevira Nov. 15 at 10:06 AM
$ATNM “We plan to establish our own manufacturing capabilities and intend to commence the build-out of a facility that will be capable of supplying final drug product for our current and planned clinical trials” Late 2025 and we are still planning, which is disappointing. Also, I thought we’d commercialise it to third parties? The verbiage here implies it’s just planned for our own clinical trials.
0 · Reply
johnny4cures
johnny4cures Nov. 15 at 5:12 AM
$ATNM pt 1 "In August 2025, we received a letter from Novartis Pharmaceuticals Corporation (the “Novartis Letter”) that is incorporated in this Form 10-Q as an exhibit. In that letter, Novartis strongly objected to statements that Actinium made comparing ATNM-400 and Pluvicto®. Given that ATNM-400 is in preclinical development and that we clearly indicated as such, we believe that the Novartis Letter is highly unusual. We believe the particular statements cited by Novartis were not misleading and were accurate depictions of our research findings that evaluated ATNM-400 versus 177Lu-PSMA-617, the active agent in Pluvicto® as well as 225Ac-PSMA-617, a targeted radiotherapy that is not yet approved but is being evaluated by multiple companies including Novartis. As we have reported, ATNM-400 demonstrated superior tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals compared to 177Lu-PSMA-617."
1 · Reply
d_risk
d_risk Nov. 15 at 12:01 AM
$ATNM - Actinium Pharmaceuticals Inc. (Delaware) Common Stock - 10Q - Updated Risk Factors ATNM’s latest 10-Q risk factors highlight new FDA trial delay risks, expanded orphan drug exclusivity details, deeper focus on U.S. healthcare reforms and government shutdowns, added risks from compliance, litigation, manufacturing, and commercialization challenges, plus new warnings on trade secrets, international operations, stock volatility, and analyst coverage. #Biopharmaceuticals #AnalystCoverage #StockVolatility #InternationalOperations #TradeSecrets #CommercializationRisk #ManufacturingChallenges #LitigationRisk #RegulatoryCompliance #HealthcareReform #OrphanDrugExclusivity #FDATrialDelays 🟢 Added 🟠 Removed https://d-risk.ai/ATNM/10-Q/2025-11-14
0 · Reply
Pinto72
Pinto72 Nov. 14 at 8:43 PM
$ATNM Looking forward to a weekend filled with @johnny4skin’s ”STELLAR” DD! 🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSH 🤣🤣🤣🤣🤣
0 · Reply
gooddoggie
gooddoggie Nov. 14 at 7:16 PM
$ATNM Green day. No not the little guy with eye shadow. Probably go to $10 next week.
2 · Reply
johnny4cures
johnny4cures Nov. 14 at 4:34 PM
$ATNM
1 · Reply
johnny4cures
johnny4cures Nov. 14 at 4:31 PM
$ATNM The company solid tumor asset ATNM-400 will most likely mimic the success of pd-1 inhibitors like Keytruda/Opdivo with recent data that show a greater efficacy and improved durability. Looking forward to the update and possible filings for speedy regulators new voucher review.
0 · Reply
luzongeezer
luzongeezer Nov. 14 at 7:01 AM
$ATNM Damned typhoon murdered our best mango tree.
0 · Reply
tjm1
tjm1 Nov. 13 at 9:48 PM
$ATNM This is what Seth does every night in his bedroom, yelling "F those investors"!
3 · Reply
Pinto72
Pinto72 Nov. 13 at 9:04 PM
$ATNM Is DONNA, still buying with both hands? 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!! 🤣🤣🤣🤣🤣
0 · Reply
Latest News on ATNM
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 18 days ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 21 days ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 4 weeks ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 4 weeks ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 3 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 5 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 6 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 7 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 7 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 7 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 7 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 8 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 8 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Xarevira
Xarevira Nov. 15 at 10:06 AM
$ATNM “We plan to establish our own manufacturing capabilities and intend to commence the build-out of a facility that will be capable of supplying final drug product for our current and planned clinical trials” Late 2025 and we are still planning, which is disappointing. Also, I thought we’d commercialise it to third parties? The verbiage here implies it’s just planned for our own clinical trials.
0 · Reply
johnny4cures
johnny4cures Nov. 15 at 5:12 AM
$ATNM pt 1 "In August 2025, we received a letter from Novartis Pharmaceuticals Corporation (the “Novartis Letter”) that is incorporated in this Form 10-Q as an exhibit. In that letter, Novartis strongly objected to statements that Actinium made comparing ATNM-400 and Pluvicto®. Given that ATNM-400 is in preclinical development and that we clearly indicated as such, we believe that the Novartis Letter is highly unusual. We believe the particular statements cited by Novartis were not misleading and were accurate depictions of our research findings that evaluated ATNM-400 versus 177Lu-PSMA-617, the active agent in Pluvicto® as well as 225Ac-PSMA-617, a targeted radiotherapy that is not yet approved but is being evaluated by multiple companies including Novartis. As we have reported, ATNM-400 demonstrated superior tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals compared to 177Lu-PSMA-617."
1 · Reply
d_risk
d_risk Nov. 15 at 12:01 AM
$ATNM - Actinium Pharmaceuticals Inc. (Delaware) Common Stock - 10Q - Updated Risk Factors ATNM’s latest 10-Q risk factors highlight new FDA trial delay risks, expanded orphan drug exclusivity details, deeper focus on U.S. healthcare reforms and government shutdowns, added risks from compliance, litigation, manufacturing, and commercialization challenges, plus new warnings on trade secrets, international operations, stock volatility, and analyst coverage. #Biopharmaceuticals #AnalystCoverage #StockVolatility #InternationalOperations #TradeSecrets #CommercializationRisk #ManufacturingChallenges #LitigationRisk #RegulatoryCompliance #HealthcareReform #OrphanDrugExclusivity #FDATrialDelays 🟢 Added 🟠 Removed https://d-risk.ai/ATNM/10-Q/2025-11-14
0 · Reply
Pinto72
Pinto72 Nov. 14 at 8:43 PM
$ATNM Looking forward to a weekend filled with @johnny4skin’s ”STELLAR” DD! 🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSH 🤣🤣🤣🤣🤣
0 · Reply
gooddoggie
gooddoggie Nov. 14 at 7:16 PM
$ATNM Green day. No not the little guy with eye shadow. Probably go to $10 next week.
2 · Reply
johnny4cures
johnny4cures Nov. 14 at 4:34 PM
$ATNM
1 · Reply
johnny4cures
johnny4cures Nov. 14 at 4:31 PM
$ATNM The company solid tumor asset ATNM-400 will most likely mimic the success of pd-1 inhibitors like Keytruda/Opdivo with recent data that show a greater efficacy and improved durability. Looking forward to the update and possible filings for speedy regulators new voucher review.
0 · Reply
luzongeezer
luzongeezer Nov. 14 at 7:01 AM
$ATNM Damned typhoon murdered our best mango tree.
0 · Reply
tjm1
tjm1 Nov. 13 at 9:48 PM
$ATNM This is what Seth does every night in his bedroom, yelling "F those investors"!
3 · Reply
Pinto72
Pinto72 Nov. 13 at 9:04 PM
$ATNM Is DONNA, still buying with both hands? 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!! 🤣🤣🤣🤣🤣
0 · Reply
greencheese500
greencheese500 Nov. 13 at 8:21 PM
$ATNM has 3 Candidates. I wonder how much each Candidates are worth. 🤔
3 · Reply
Pickerbefore
Pickerbefore Nov. 13 at 7:34 PM
$ATNM wait till the quarterly report comes out. Disclosure of what Seth has done and how much he received for doing nothing. New lows coming.
0 · Reply
Jimmy1940
Jimmy1940 Nov. 13 at 4:29 PM
$ATNM 52 Week Range $1.03 - $2.41 I've lost my money and now, my mind
2 · Reply
luzongeezer
luzongeezer Nov. 13 at 11:52 AM
$ATNM Tutes down to 18%.
0 · Reply
Pinto72
Pinto72 Nov. 12 at 9:00 PM
$ATNM 🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣
0 · Reply
luzongeezer
luzongeezer Nov. 12 at 1:09 PM
$ATNM Falling MONITORS here, doggie. Not your pissant iguanas!
1 · Reply
mauryrosen
mauryrosen Nov. 12 at 1:36 AM
$ATNM https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-opens-new-plant-california-make-cancer-drugs-2025-11-10/
0 · Reply
Pinto72
Pinto72 Nov. 11 at 10:49 PM
$ATNM Just shows you that shorts are not the ones brining this DOOOOOWN📉📉📉📉📉 The next round of dilution will accelerate reverse value!🚀🚀🚀🚀🚀 $0.20 AS SOON!!!! 🤣🤣🤣🤣🤣
0 · Reply
Biotrad3r
Biotrad3r Nov. 11 at 10:43 PM
$ATNM Short Interest was published this afternoon. Still very low %. Only went up .10% from 2.72 to 2.82%
1 · Reply
Pinto72
Pinto72 Nov. 11 at 8:50 PM
$ATNM DOOOOOOOWN AGAIN!!!!! HELLO, AAVIE 🚀🚀🚀🚀🚀🚀🚀 eXtTeEmLeE bUlLiSh!!! 🤣🤣🤣🤣🤣🤣
0 · Reply
Arcides
Arcides Nov. 11 at 6:01 PM
$ATNM first loss is best loss.
0 · Reply
gooddoggie
gooddoggie Nov. 11 at 3:44 PM
$ATNM @englishkaren Watch for falling iguanas.
1 · Reply